Screener
Monopar Therapeutics MNPR Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | For the Three Months Ended / March 31, 2026 | For the Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash proceeds from the issuance of stock upon exercise of stock options | — | 15,447 |
| Net cash provided by (used in) financing activities | (200,203) | (115,682) |
| Effect of exchange rate and valuation changes on cash equivalents | (31,628) | (54) |
| Net increase (decrease) in cash and cash equivalents | (9,289,289) | (6,104,880) |
| Cash and cash equivalents at beginning of period | 61,833,552 | 45,816,289 |
| Cash and cash equivalents at end of period | $52,544,263 | $39,711,409 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Lease liability arising out of obtaining right-of-use asset | $291,726 | $9,903 |
Document
FAQ
- What is Monopar Therapeutics's net change in cash?
- Monopar Therapeutics (MNPR) reported net change in cash of -$9.29M in Q1 2026.
- How has Monopar Therapeutics's net change in cash changed year-over-year?
- Monopar Therapeutics's net change in cash decreased by 52.2% year-over-year, from -$6.1M to -$9.29M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Monopar Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude